Pharmacological characteristics of new oral anticoagulants;Pharmakologie neuer oraler Antikoagulantien - Grundlage für rationale Entscheidungen

Klinikarzt

Volumn 41, Issue SUPPL. 1, 2012, Pages 10-15

  Kreutz, Reinhold ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Anticoagulant; pharmacodynamics; pharmacokinetics drug interactions; pharmacology

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; RIVAROXABAN; THROMBIN INHIBITOR;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL PRACTICE; HEMODYNAMIC MONITORING; HUMAN; KIDNEY DYSFUNCTION; PHARMACODYNAMICS;

EID: 84859800808     PISSN: 03412350     EISSN: 14393859     Source Type: Journal    
DOI: 10.1055/s-0032-1312456     Document Type: Article

References (15)

1. Turpie AG, Esmon C. Venous and arterial thrombosis-pathogenesis and the rationale for anticoagulation. Thromb Haemost: 2011; 105 586 596
2. Eriksson BI, Quinlan DJ, Eikelboom JW. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Ann Rev Med: 2011; 62 41 57
3. Potpara TS, Lip GY. New anticoagulation drugs for atrial fibrillation. Clin Pharmacol Ther: 2011; 90 502 506
4. Pradaxa 150 mg Hartkapseln. Fachinformation: 11 2011
5. Xarelto 20 mg Filmtabletten. Fachinformation: 12 2011
6. ELIQUIS 2,5 mg Filmtabletten. Fachinformation: 05 2011
7. Hankey GJ, Eikelboom JW. Dabigatran etexilate: anew oral thrombin inhibitor. Circulation: 2011; 123 1436 1450
8. Rosskopf D, Kroemer HK, Siegmund W. Pharmacokinetic problems in clinical practice: role of drug transporters. Dtsch Med Wschr: 2009; 134 345 356
9. Kreutz R. Pharmacodynamic and pharmacokinetic basics of rivaroxaban. Fundam Clin Pharmacol: 2012; 26 27 32
10. Prom R, Spinler SA. The role of apixaban for venous and arterial thromboembolic disease. Ann Pharmacother: 2011; 45 1262 1283
11. Clemens A, Haertter S, Friedman J, Brueckmann M, Stangier J, van RJ, Lehr T. Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification. Curr Med Res Opin: 2012; 28 195 201
12. Misselwitz F, Berkowitz SD, Perzborn E. The discovery and development of rivaroxaban. Ann N Y Acad Sci: 2011; 1222 64 75
13. Harder S. Renal Profiles of Anticoagulants. J Clin Pharmacol: 05 2011
14. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron: 1976; 16 31 41
15. Harenberg J, Bauersachs R, Diehm C, Lawall H, Burkhardt H, Gerlach H, Darius H, Voller H, Rabe E, Wehling M. Anticoagulation in the elderly. Internist: 2010; 51 1446 1455